Depo Promone is relevant in clinical settings marked by temporary physiological imbalance, applied across therapeutic areas in veterinary medicine.

Controlling the Estrus Cycle and Providing Long-Term Contraception

This medication is primarily used for reproductive cycle management, and provides supportive relief that helps manage symptoms associated with the heat cycle (estrus suppression or postponement) and hormonal contraception in female dogs and cats. The injection is applied in contexts requiring temporary, long-acting control over the animal's fertility and reproductive status, and provides a management option for temporary reproductive control. It is commonly used across conditions presenting with symptoms related to cycle control, pseudo-pregnancy, and certain hormone-driven behavioral patterns.

---

Symptom Management and Therapeutic Support

This medication is used in situations involving certain distressing symptoms linked to sex-hormone physiological disorders, most commonly pseudo-pregnancy in dogs. The benefit supports the patient during difficult episodes by easing distress and managing symptoms that create noticeable physiological strain, assisting with maintaining functional stability during symptomatic periods. Depo Promone assists with moderating unwanted behaviors that are a direct result of sex hormone activity, spanning various patient groups. This medication assists with managing symptom clusters that may become intense or disruptive, helping to address symptoms related to heightened physiological activity that interfere with daily functioning, which supports general well-being.

“The primary application is supporting the animal through symptomatic periods by providing temporary reproductive quiescence.”

---

Quick Fact: Relief for Hormonal Distress

Property	Description
Primary Indication	Estrus suppression and cycle postponement
Symptom Category	Behavioral and physiological symptoms of systemic hormonal imbalance
Key Benefit	Contributes to easing the overall symptom load during periods of heightened reproductive activity

The eligibility for Depo Promone is strictly defined by regulatory authorities for the target species of female dogs (bitches) and cats (queens).

Eligibility and Exclusion Status

Category	Regulatory Status	Status Detail
Target Population	Allowed	Adult non-pregnant female dogs and cats in the Anestrus Phase only.
Life Stage	Contraindicated	Females before their first estrus (pre-pubertal) and Gravid Bitches (pregnant females).
Reproductive Cycle	Contraindicated	Use is prohibited during Pro-oestrus, Oestrus, or Metoestrus (active heat cycles).
Prior Health	Contraindicated	Animals with a history of genito-urinary disease, mammary tumours, or persistent/abnormal vaginal discharge.
Special Conditions	Restricted Use	Animals with Diabetes Mellitus require close observation. The medicine is not recommended for those primarily intended for breeding purposes.

Regulatory Context

Use is prohibited if the animal has certain abnormalities of the endocrine or reproductive system, or if a previous dose caused mammary swelling and lactation; re-administration is not allowed in these individuals. The drug's use is contingent on the strict classification of the animal's reproductive status and health history as defined in official prescribing information.

Interactions with Other Medicines and Products

Depo Promone (medroxyprogesterone acetate) can interact with other drugs and herbal products, primarily those that affect certain liver enzymes. These interactions can potentially decrease the contraceptive effectiveness of Depo Promone.

Category or Specific Agent	Interaction Mechanism and Effect
Enzyme Inducers (e.g., strong CYP3A inducers)	Decrease the concentration of medroxyprogesterone acetate in the blood, potentially reducing efficacy. Examples include rifampin, phenytoin, carbamazepine, phenobarbital, and St. John's wort (herbal product).
Aminoglutethimide	May significantly decrease the serum concentration of medroxyprogesterone acetate.
Enzyme Inhibitors (e.g., strong CYP3A inhibitors)	Expected to increase the concentration of medroxyprogesterone acetate, though clinical significance is not consistently defined in all formulations.
Anticonvulsants/Corticosteroids	Chronic use of drugs that can reduce bone mass may compound the risk of bone mineral density loss associated with Depo Promone use.

Impact on Laboratory Tests

This medication can interfere with the results of certain laboratory tests. Progestin therapy may decrease plasma and urinary steroid levels, gonadotropin levels, and sex-hormone-binding globulin concentrations. The treating pathologist should be advised of progestin therapy when relevant specimens are submitted.

Specific Patient Monitoring

Patients with diabetes must be monitored carefully due to the potential for a decrease in glucose tolerance associated with progestin use.

Suppression of the HPO Axis and Ovulation

Depo Promone (medroxyprogesterone acetate) works by engaging mechanisms that regulate the Hypothalamic-Pituitary-Ovarian ( HPO) axis. Acting as a progestin, it binds to progesterone receptors within the hypothalamus and pituitary gland. This receptor binding initiates a negative feedback loop, which reduces the release of Gonadotropin-Releasing Hormone and subsequently the pituitary gonadotropins, luteinizing hormone ( LH) and follicle-stimulating hormone ( FSH). This suppression of the central hormonal signaling cascade results in the absence of ovum release (anovulation).

---

Alteration of Peripheral Tissue Barriers

The drug also modulates activity within distinct peripheral biological systems by targeting reproductive tissues. It initiates signaling sequences in the cervix which results in thickened cervical mucus. Simultaneously, it modifies gene expression within the endometrium (uterine lining), causing it to become thin and inactive. This mechanistic domain results in specific physiological changes through the modification of cervical and endometrial tissue states.

Administration Map: How to use Depo Promone

Administration Scope	Detail
Route of administration	Subcutaneous (SC) injection is the utilized parenteral route for this suspension.
Dosing schedule	Standard single dose is 1 mL (equivalent to 50 mg MPA) for both bitches (dogs) and queens (cats).
Timing in relation to meals (if applicable)	Not applicable.
Preparation requirements (if applicable)	The vial must be shaken thoroughly before use to ensure the active drug is uniformly suspended.
Age-group administration rules	Not defined by age; use is restricted by reproductive state.
Missed-dose rules	Not specified in general use instructions; the next administration must be scheduled based on the recommended repeat interval.
Special procedural conditions	Administration is conducted only during the anestrus period. The injection is typically performed in an inconspicuous area, such as the inner fold of the flank.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Parenteral injection (Subcutaneous).
Frequency pattern	Intermittent use; based on 4- or 6-month cycles specific to the animal species.
Standardization basis	Established veterinary medical protocols.
Use-context constraints	Strict dependence on the reproductive cycle stage; required to be administered during anestrus.

---

Resulting Procedural Structure

Step sequence

• The vial must be shaken vigorously to ensure the active substance is uniformly suspended.
• The animal must be confirmed to be in the anestrus stage of the reproductive cycle.
• The standard dose of 1 mL (50 mg) is administered via a single subcutaneous injection.
• The next administration is scheduled for a 4- to 6-month interval.

Connection to the overall use protocol (2–4 sentences):

The administration model is strictly dependent on the animal's reproductive state. This procedure utilizes a non-oral subcutaneous route with a fixed 1 mL volume and requires careful preparation and precise timing within the anestrus phase. The use is structured around predictable, multi-month cycles for long-term management.

Evidence for Temporary Control of the Reproductive Cycle

Research has studied medroxyprogesterone acetate (MPA) in the context of the reproductive cycle and in research exploring temporary long-acting hormonal contraception in female dogs and cats. The evidence base includes a combination of smaller, randomized controlled trials (RCTs) and extensive observational studies. Researchers focused on measuring specific outcomes like the duration of the cycle interval and hormonal shifts examined in relation to ovulation.

Studies report measurements of the interestrus interval and data show patterns related to estrus behaviors in the observed populations. The overall evidence level for this primary application is described as Moderate by scientific reviews. However, the research record indicates limitations regarding prolonged or repeated use. Long-term outcomes following repeated administration are not fully characterized, reflecting an area where long-term outcomes are not fully established.

Evidence for Managing Symptoms of Pseudo-pregnancy

Research was studied for managing specific behavioral and physiological symptoms associated with canine pseudo-pregnancy. This evidence is primarily supported by historical case reports, older comparative efficacy studies, and reviews. Studies explored outcomes such as changes in maternal behaviors and measured shifts in physical symptoms.

Available research describes clinical patterns observed. The overall evidence level for this specific application is generally described as Low. The evidence base is limited, providing limited information into the outcomes compared to other available approaches.

Durability and Long-Term Follow-up Studies

Research was studied for the duration of the reproductive cycle interval. Study follow-up has varied widely, ranging from short-term monitoring (3 to 6 months post-injection) to extended observational periods. Consistent, dedicated long-term follow-up protocols for repeated administrations are not fully established, meaning data for long-term outcomes remains limited for certain groups.

What is Still Uncertain in the Research Record

The research record highlights several areas where data are still emerging or where uncertainty remains. Evidence quality varies across studies, and many older trials had sample sizes that were modest. Limitations emphasize that prolonged use was associated with observations that contribute to a lack of certainty regarding long-term outcomes. These findings contribute to the broader evidence landscape but do not determine whether an individual animal will respond similarly or provide personal outcomes.

Key Studies & References

1. Assessment of Human-originated Medroxyprogesterone Acetate (MPA) as Effective Contraceptive in Domesticated Queens (Felis catus)
2. Canine Pseudopregnancy: A Review

Common questions about Depo Promone (FAQ)

Q: How often do people typically need to get the Depo Promone shot?

Official documents state that the injection is typically administered on an intermittent schedule, with the repeat dose generally scheduled after a 6-month interval for dogs and a 4-month interval for cats. Regulatory documents state this schedule is contingent on confirming the individual is in the anestrus stage of the reproductive cycle when the dose is given.

Q: Is it possible for Depo Promone to cause changes in skin texture or acne?

Regulatory information indicates that changes may occur at the injection site, specifically describing a potential thinning appearance of the skin in that area. However, the official safety documentation does not specifically list acne as a commonly reported change or adverse reaction associated with this treatment.

Q: How long after getting the injection does the medicine begin to work?

The unique design of the medicine is a depot injection, meaning the active compound is released slowly from the injection site to create a sustained, long-acting effect. While the mechanism of action begins upon administration, the regulatory information does not quantify a specific timeline for the clinical onset of the full effect.

Q: How long does it take for Depo Promone to be fully cleared from the body?

The active ingredient is formulated to be long-acting, and the time it takes for its effects to cease is highly variable among individuals. Official information notes that the return to the normal reproductive cycle after treatment can range from several months to a few years. This variability reflects the sustained nature of the drug’s effect in the body.

Q: Can Depo Promone cause hair to thin or change?

Regulatory documents state that changes may occur at the injection site itself. These changes can include the hair thinning or a change in the color of the hair in the area where the suspension was administered.

Q: Does the effectiveness of Depo Promone change over time?

Studies and official information indicate that while some individuals can maintain estrus suppression for a sustained period, repeated use may lead to a variable response. Regulatory warnings mention that the effectiveness may change over time, resulting in the onset of the heat cycle after a variable period despite continued treatment.

Q: What happens in the body when the treatment with Depo Promone is stopped?

When treatment is stopped, the body will gradually return to its normal reproductive cycle. Official sources confirm that the time taken for this return is highly variable and can range from several months to a few years, as the long-acting formulation takes time to clear the system.

Q: Is Depo Promone used for conditions other than what is listed in the main uses?

According to the official product information, the primary uses are for the prevention of estrus (the heat cycle). The drug is also used in specific circumstances for gestation management, which involves extending the date of a new pregnancy.

Q: Is the injection usually given in a specific part of the body?

Official procedural guidelines describe the injection as being administered subcutaneously in an inconspicuous area of the body. Recommended areas include the inner surface of the thigh or the inner fold of the flank.

Q: What research exists on the use of Depo Promone in adolescents?

The official product label addresses use in this population by stating that the drug is contraindicated, or prohibited, for use in young females who have not yet had their first estrus (pre-pubertal). The regulatory status indicates that use is restricted and contingent on the individual's reproductive state.

Q: Is it true that Depo Promone can cause temporary changes to the menstrual cycle?

The drug’s main function is to suppress the reproductive cycle entirely and prevent estrus (the heat cycle). This fundamental effect is described as a cessation of the normal cycle while the drug is active.

Q: How is the effect of Depo Promone measured or monitored?

The individual's phase of the reproductive cycle should be determined before the product is administered, potentially by performing a vaginal smear. This is a measure to confirm the correct starting condition for the treatment.

Q: What is the difference between Depo-Provera and Depo Promone?

Although both contain the active ingredient medroxyprogesterone acetate (MPA), the products are distinctly different. Depo Promone is officially classified as a veterinary product used for estrus prevention in dogs and cats. Depo-Provera is a separate, human-use product for contraception and other medical conditions.

Q: Why do some official sources mention a limit on the duration of use for Depo Promone?

The concern surrounding the duration of use is linked to serious adverse reactions that are associated with prolonged exposure. Regulatory warnings cite potential risks such as Cystic Endometrial Hyperplasia (CEH) and the possible worsening of conditions like Diabetes Mellitus.

The storage and disposal of Depo Promone (medroxyprogesterone acetate injectable suspension) must strictly follow regulatory guidance to ensure product stability and safety.

Storage Requirements

The medicine must be stored at a controlled room temperature, generally defined as not above 25°C (77°F). It is mandatory to not freeze the suspension. Vials must be stored upright and kept in the original carton to protect the product from light. Before use, the suspension must be shaken well to ensure the contents are homogeneous.

Disposal and Safety

Depo Promone is for single use only. Any unused medicine or expired product must be disposed of according to local pharmaceutical waste regulations and must not be thrown into household waste or wastewater. For safety, the product must be kept out of the sight and reach of children and animals.